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Specific Aims 
1. Design and synthesize a-ketoamide transition-state inhibitors with selectivity for caspase-3, caspase-6, 
and caspase-8. 
2. Design and synthesize potent and specific aza-epoxide inhibitors for caspase-3, caspase-6, and caspase-
8. 
3. Synthesize libraries of aza-epoxide caspase inhibitors. 
4. Assay all new inhibitors for specificity with available caspases and other enzymes. 
5. Assay a few potent inhibitors for their ability to inhibit apoptosis. 
P rogress R e p o r t 
Per iod C o v e r e d : September 1, 1999 to August 31 , 2006. 
S u m m a r y . Caspases are members of the CD clan of cysteine proteases. Other members of the clan 
include clostripain, legumain, gingipain, and separase. During this research, we have discovered three new 
classes of irreversible inhibitors: aza-peptide epoxides, aza-peptide Michael acceptors, and ally I sulfones. The 
aza-peptide epoxides and aza-peptide Michael acceptors are highly specific for clan CD cysteine proteases. 
They have little or no inhibitory potency toward clan CA cysteine proteases (papain, calpain, and cathepsin B), 
serine proteases, aspartate proteases, or the proteasome. Within clan CD cysteine proteases, aza-peptide 
epoxides and aza-peptide Michael acceptors show high specificity toward their targeted clan CD protease. 
Thus, caspase inhibitors don't react with legumain or gingipain, while legumain inhibitors don't react with 
caspases or gingipain. Considerable selectivity for individual caspases has been obtained by changing both the 
P and P' residues. Allyl sulfones, which we have not developed extensively, appear to be selective for the clan 
CA cysteine proteases. Aza-peptide epoxides and aza-peptide Michael acceptors appear to be the most selective 
classes of inhibitor for caspases and other clan CD cysteine proteases. Previously described inhibitors for 
caspases have been shown to inhibit effectively clan CA cysteine proteases such as the cathepsins (Rozman-
Pungercar, Kopitar-Jerala et al. 2003). Thus, our new inhibitors have great potential for elucidating the 
biological function of clan CD cysteine proteases and for therapeutic uses. In addition to clan CD cysteine 
protease, we discovered late in the project that aza-peptide epoxides were inibitors for the main protease from 
the SARS coronavirus. Unfortunately, we were unable to pursue this new avenue of research since this grant 
was not renewed. 
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Specific Aims. The specific aims of our prior proposal are listed above. W e made good progress on all 
of these specific aims. In the course of this research, we discovered that aza-peptide inhibitors are highly 
specific for clan CD cysteine proteases. Although the original specific aims only proposed work with caspases, 
we have extended the aza-peptide design and the scope of our research to other clan CD cysteine proteases, 
particularly legumains and gingipains, as these enzymes have been described in the literature and have become 
available for kinetic inhibition assays during the period of this grant. We also extended the design to the main 
protease from the SARS coronavirus. 
a-Ketoamide Calpain Inhibitors (Specific Aim 1). The Pi's laboratory has previously synthesized a 
variety of dipeptidyl and tripeptidyl ct-keto esters, ct-keto amides, and ct-keto acid transition-state inhibitors of 
the cysteine proteases calpain I and II (Li, Patil et al. 1993; Li, Ortega-Vilain et al. 1996). These compounds 
are potent inhibitors of both calpain I and calpain II with Kj values as low as 0.020 uM. One of these 
compounds (AK295) has been studied extensively in stroke and head injury models and is effective at 
preventing peripheral neuropathy (collaboration with J. Glass, Emory University (Wang, Davis et al. 2004)). 
With support from BASF in the mid-1990s, the Pi's research group synthesized over 50 peptide a-ketoamides 
with P I Asp residues as inhibitors for caspase 1. Many of the compounds are potent caspase 1 inhibitors with 
Kj values in the low nanomolar range (i.e., Ac-Tyr-Glu-Val-Asp-CONHCILjCE^Ph, Kj = 0.4 nM). During this 
grant period, we extended this inhibitor design to caspase 3, 6, and 8. We synthesized a number of new 
tetrapeptide ketoamides which are listed in Table 4. The compounds are slow-binding transition-state inhibitors 
of caspases 3, 6, and 8 and both initial and final Kj values in u M are reported also in Table 4. 
Table 4. Caspase 3 Caspase 6 Caspase 8 
Ki( ini t ial) K-i(final) K-i(initiat) K-i(fmal) K-i(initial) K j 
Z-Val -Glu-Val -Asp-CO-NH-(CH 2 ) 2 Ph 0.317 u M 0.243 0.126 0.080 0.042 0.029 
Z-Leu-Glu-Thr-Asp-CO-NH-CH 2 Ph 3.638 0.762 0.968 0.156 0.125 0.011 
Z-Leu-Glu-Thr-Asp-CO-NH-(CH 2 ) 2 Ph 2.588 0.564 1.191 0.153 0.187 0.003 
Z-Leu-Glu-Tlrr -Asp-CO-NH-(CH 2 ) 3 Ph 3.249 0.733 1.972 0.461 0.120 0.013 
Z-Leu-Glu-Thr -Asp-CO-NH-(CH 2 ) 3 OCH 3 2.905 0.679 1.619 0.363 0.094 0.006 
Four inhibitors utilized the predicted optimal sequence for caspase 8, Cbz-Leu-Glu-Thr-Asp. The other 
had a caspase 6 optimal sequence, Cbz-Val-Glu-Val-Asp. All four of the Cbz-Leu-Glu-Thr-Asp a-keto amides 
were potent inhibitors of caspase 8, with K i ( f i n a i ) values ranging from 3 nM to 13 nM. Interestingly, the 
compound design based on the caspase 6 optimal sequence, Z-Val -Glu-Val -Asp-CO-NH-(CH 2 ) 2 Ph, was also an 
extremely potent inhibitor of caspase 8 with a K i ( f i n a i ) value of 29 nM. The most potent compound of the series 
was Cbz-Leu-Glu-Thr-Asp-CO-NH-(CH 2 ) 2 Ph, which had a K p n a i ) of 3 nM, and was twice as potent as the next 
best inhibitor, Z-Leu-Glu-Thr -Asp-CO-NH-(CH 2 ) 3 OCH 3 ( K l ( f i n a i ) = 6 nM). Several of the inhibitors 
demonstrated selectivity between the three caspases studied. Cbz-Leu-Glu-Thr-Asp-CO-NH-(CH 2 ) 2 Ph was 51 
times more potent against caspase 8 than caspase 6, and 188 times more potent than against caspase 3. The 
methoxypropyl tetrapeptide derivative showed similar selectivity, with a 61-fold greater potency against 
caspase 8 than caspase 6, and a 113-fold greater potency than shown against caspase 3. W e found that ct-
ketoamides with caspase specific sequences were difficult to synthesize and, thus, devoted most of our efforts 
toward aza-peptide inhibitors. 
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Nomenclature. We will use the subsite nomenclature of Schechter & Berger (Schechter and Berger 
1967) to describe the individual residues of the inhibitors and the corresponding subsites of the enzyme. The 
primary substrate binding site of caspases is S I , which recognizes the PI Asp residue in substrates and 
inhibitors. The nomenclature is shown in the following figure. In this proposal we refer to aza-peptides as 
inhibitor structures in which the PI amino acid residue is replaced by an aza-amino acid where the a-carbon of 
the amino acid is replaced by a nitrogen atom. An aza-aspartic acid residue is shown below (1). In peptide 
sequences this will be abbreviated AAsp or aD when using the amino acid one letter code. Other abbreviations 
used in this proposal are listed at the end of the Research Plan (Page 57). 
S1 
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We have synthesized, thus far, over 40 aza-peptide epoxide caspase inhibitors. Table 5 shows 
representative kinetic data obtained with caspase 1, 3, 6 and 8. The reported second order inhibition rates ( k 2 
values in M 'V 1 ) with caspases 1, 3, 6, and 8 ranged up to 1,910,000 M 'V 1 (James, Asgian et al. 2004). In 
general, the caspase 1 sequence Val-Ala-AAsp was most reactive with caspase 1, the caspase 3 sequence Asp-
Glu-Val-AAsp was most reactive with caspase 3, the sequence Ile-Glu-Thr-AAsp was most reactive with 
caspase 6, and the caspase 8 sequence Leu-Glu-Thr-AAsp was most reactive with caspase 8. In table 5, we 
abbreviate the aza-aspartic acid as AAsp and the epoxide as EP. To understand the specificity and selectivity of 
the inhibitors at the P f position, we have changed the substituents on the epoxide moiety (3) from a simple alkyl 
groups (Y = C H 2 C H 2 P h ) to esters (Y = C O O R 4 ) , amides (Y = C O N H R 5 ) or amino acids (Y = CO-AA-R^). We 
sought to obtain increased selectivity by utilizing interactions with the S' subsites of the various caspases. Some 
of the more specific inhibitors for individual caspases are shown in bold in Table 5. The compound numbers 
are from our publication (James, Asgian et al. 2004). 
T a b l e 5. caspase 1 caspase 3 caspase 6 caspase 8 
23c PhPr-Val-Ala-AAsp-EP-COOEt S,S 32,200 M" V 1040 75 1570 
R,R 6290 NI NI NI 
23g PhPr -Va l -Ala -AAsp-EP-CONHCH 2 Ph S,S 65,900 1610 155 9360 
R,R 1630 NI NI NI 
231 PhPr-Val -Ala-AAsp-EP-CO-Phe-NH 2 S,S 32,700 625 65 390 
R,R 330 NI NI NI 
25c Cbz-Asp-Glu-Val-AAsp-EP-COOEt S,S 11,800 1,070,000 5440 95,500 
R,R 4320 464,000 475 785 
25d Cbz-Asp-Glu-Val -AAsp-EP-COOCH 2 Ph S,S 54,700 1,910,000 12,700 188,000 
26c Cbz-Leu-Glu-Thr-AAsp-EP-COOEt S,S 25,700 3210 8620 61,200 
R,R 19,600 3250 4390 34,700 
26d Cbz-Leu-Glu-Thr -AAsp-EP-COOCH 2 Ph S,S 43,500 3520 10,300 72,700 
27d Cbz- I le -Glu-Thr-AAsp-EP-COOCH 2 Ph S,S 45,800 9500 86,200 58,500 
R,R 13,000 3110 45,400 4560 
PhPr = PhCH 2 CH 2 CO-, NI = no inhibition, EP = epoxide (-C 2 H 2 0-) , AAsp = aza-Asp, Cbz = PhCH 2CO-. 
Ste reochemis t ry . The epoxide moiety in aza-peptide epoxides has two chiral centers and the 
stereochemistry at these centers plays an important role in the potency of the inhibitor. In general, the order of 
reactivity of aza-peptide epoxides was S,S > R,R > trans > cis (Table 5). In comparing the rates of inhibition of 
caspase 1 by the S,SIR,R pairs (PhPr-Val-Ala-AAsp-EP-Y), we observed that the S,S isomer was more reactive 
by a factor of 5 to 100. With caspase 3, a comparison of the S,SIR,R pair for Cbz-Asp-Glu-Val-AAsp-EP-
COOEt (25c) gave a ratio of 2. With caspase 6, comparison of the S,SIR,R pairs (Cbz-Ile-Glu-Thr-AAsp-EP-Y) 
gave ratios of 1 to 2. With caspase 8, comparison of the S,S/R,R pairs (Cbz-Leu-Glu-Thr-AAsp-EP-Y and Cbz-
l le-Glu-Thr-AAsp-EP-Y) gave ratios of 2 to 13. Thus, it appears that the epoxide stereochemistry was less 
significant with caspases 3, -6, and -8 than with caspase 1. Interestingly, some of the RJl epoxides while being 
less potent are actually more selective than the S,S epoxides. Almost all of the caspase 1 aza-peptide epoxides 
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Aza-pep t ide Inh ib i to r s (Specific A im 2, 3 , a n d 4). Aza-peptide epoxides were designed based on the 
structure of a good peptide substrate (2) with the placement of the carbonyl group of the epoxide moiety in a 
location identical to that of the carbonyl of the scissile bond in a substrate (3). Replacement of the a-carbon of 
the amino acid residue at PI with a nitrogen results in the formation of an aza-amino acid residue. For example, 
in the design of the aza-peptide epoxide inhibitors for caspases, the a-carbon of the PI Asp residue was 
converted to a nitrogen atom to obtain an aza-Asp residue (which will be abbreviated as AAsp) . This novel 
group of irreversible inhibitors was found to be highly specific for cysteine proteases of clan CD, particularly 
caspases (Asgian, James et al. 2002; James, Asgian et al. 2004). Once we discovered the high selectivity of 
these inhibitors, we extended the design and synthesized aza-peptide Michael acceptor inhibitors (4) which are 
also selective for clan CD cysteine proteases (Ekici, Gotz et al. 2004). 
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with R,R stereochemistry (PhPr-Val-Ala-AAsp-(2/?,3i?)-EP-Y, 23) reacted only with caspase 1, although at 
slow rates, and showed no inhibition of caspases 3, -6, and -8 (Table 5). The R,R isomer of 25c (Cbz-Asp-Glu-
Val-AAsp-EP-COOEt) was almost as reactive an inhibitor with caspase 3 as the S,S isomer, but was much more 
selective and was 105-fold, 975-fold, and 590-fold more reactive with caspase 3 than with caspase 1, -6, and -8, 
respectively. 
Caspase a n d C lan C D Selectivity (Specific A im 4). As expected, overall the most potent inhibitors 
had the preferred substrate sequence for the target caspase. The most potent caspase 1 inhibitors, such as PhPr-
Val-Ala-AAsp-(S,£)-EP-CONHCH 2 Ph (23g), have the optimal caspase 1 peptide recognition sequence PhPr-
V A D . The most potent caspase 3 inhibitors, such as Cbz-Asp-Glu-Val -AAsp-(£S)-EP-COOCH 2 Ph (25d), have 
the optimal caspase 3 peptide recognition sequence DEVD. In addition, the most potent caspase 6 inhibitors, 
such as Cbz-Ile-Glu-Thr-AAsp-(£, .S)-EP-COOCH 2 Ph (27d), have the optimal caspase 6 peptide recognition 
sequence IETD. The only exception was caspase 8, where the caspase 3 tripeptide (Cbz-Glu-Val-AAsp-^^S)-
EP-COOEt) with the EVD sequence was better than the caspase 8 peptide recognition sequence LETD (26d, 
Cbz-Leu-Glu-Thr -AAsp- (£S>EP-COOCH 2 Ph) . 
In general, the inhibitors designed for each caspase do inhibit other caspases somewhat, just not as 
potently as the one for which they were designed. The most specific, although not the most potent, inhibitor for 
caspase 1 was PhPr-Val-Ala-AAsp-(S,S)-EP-CO-Phe-NH 2 (231, k 2 = 32,700 M 'V 1 ) which was 52-fold, 504-
fold, and 84-fold more reactive with caspase 1 than caspase 3, caspase 6, and caspase 8, respectively. The most 
specific and still quite reactive inhibitor for caspase 3 was Cbz-Asp-Glu-Val-AAsp-(^ i?) -EP-COOEt (25c, k 2 = 
464,000 M"'s" 1) which was 107-fold, 977-fold, and 591-fold more reactive with caspase 3 than caspase 1, 
caspase 6, and caspase 8, respectively. The most specific inhibitor for caspase 6 was Cbz-Ile-Glu-Thr-AAsp-
( i ^ ) - E P - C O O C H 2 P h (27d, k 2 = 45,400 M 'V 1 , a moderate inhibitor) which was 3.4-fold, 14.5-fold, and 10-
fold more reactive with caspase 6 than caspase 1, caspase 3, and caspase 8, respectively. The most specific for 
caspase 8 was C b z - L e u - G l u - T h r - A A s p - ^ ^ - E P - C O O E t (26c, k 2 = 61,200 M"V, a moderate inhibitor) which 
was 2.3-fold, 19-fold, and 7-fold more reactive with caspase 8 than caspase 1, caspase 3, and caspase 6, 
respectively. 
To show that aza-peptide epoxides designed for caspases do not react with other clan CD enzymes, 
some of our caspase inhibitors were also tested with the clan CD enzyme legumain by W. Carter and Dr. Barrett 
at the Strangeways Research Institute, UK. The aza-peptide epoxides designed for caspases were specific for 
caspases as the ko b s / [ I ] values with legumain rang ed from 1 5 - 8 6 M 'V 1 for inhibitors 23d (PhPr-Val-Ala-
A A s p - / r a ^ - E P - C O O C H 2 P h ) , 24c ( C b z - G l u - V a l - A A s p - ^ ^ - E P - C O O E t ) , 25c (Cbz -Asp-Glu -Va l -AAsp-^S) -
EP-COOEt) , and 26c (Cbz-Leu-Glu-Thr-AAsp-EP-COOEt, both isomers) (Asgian, James et al. 2002). More 
importantly, two inhibitors, 23a (PhPr -Va l -Ala -AAsp- / ra^ -EP-CH 2 CH 2 Ph) and 25c (Cbz-Asp-Glu-Val-AAsp-
( i^ i^ -EP-COOEt ) , showed no reactivity with legumain at all, as more than 90 % of the legumain activity 
remained after a ten minute incubation period (inhibitor concentrations ranged from 100 \xM to 100 nM). In 
contrast, aza-peptide epoxides, such as Cbz-Ala-Ala-AAsn-OS^-EP-COOEt, which were designed with 
sequences specific for legumain, were potent legumain inhibitors with second-order rate constants (kob s/[I] 
values) up to 43,000 M 'V 1 . 
Specificity W i t h N o n - C l a n C D Pro teases (Specific A i m 4). The aza-peptide epoxides designed for 
caspases show little to no inhibition of the clan CA cysteine proteases papain, cathepsin B, and calpain. The 
inhibitors PhPr -Val -Ala -AAsp-EP-CH 2 CH 2 Ph (23a), Cbz-Asp-Glu-Val-AAsp-EP-COOEt (25c, both isomers), 
and Cbz-Leu-Glu-Thr-AAsp-EP-COOEt (26c, both isomers) at 208 u M showed no inhibition of papain and 
cathepsin B after 80 minutes of incubation. The inhibitor PhPr -Va l -Ala -AAsp- / r a^ -EP-COOCH 2 Ph (23d, 208 
uM) had a second order rate constant (kobs/[I]) of < 10 M~ls~l with papain and cathepsin B after 80 minutes of 
incubation. Our caspase inhibitors do not inhibit clan CA cysteine proteases, but we also wanted to determine if 
aza-peptide epoxides designed with sequences specific for clan CA enzymes were reactive. Examples of these 
compounds are Ac-Leu-ALeu-EP-COOEt, Cbz-Phe-ALeu-EP-COOEt, Cbz-Leu-AAbu-EP-COOEt, Cbz-Leu-
AHph-EP-COOEt , and Cbz-Leu-Leu-ALeu-EP-COOEt. Inhibition constants (ko b s /[I]) were less than or equal 
to 20 M 'V 1 (unpublished results) with papain, cathepsin B, and calpain. The aza-peptide epoxide Suc-Np2-
ALeu-/rarcs-EP-COOEt (where Np2 = 2-naphthylalanine) was designed for cathepsin F and tested by Dr. 
Bromme at the Mount Sinai School of Medicine with cathepsins F, K, L, and S. Time-dependent inhibition was 
not observed and the inhibition ranges were greater than 100 uJVl for cathepsins K and L, and between 50-100 
u.M for cathepsins F and S. Clearly, this aza-peptide epoxide design is specific for clan CD cysteine proteases. 
The aza-peptide epoxide Cbz-Leu-Leu-ALeu-EP-COOEt was actually designed to inhibit the 
proteasome, a threonine protease. This compound, tested by Dr. Orlowski at Mount Sinai School of Medicine, 
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showed no inhibition of the proteasome. It was also important to test for specificity against serine proteases, 
such as chymotrypsin and granzyme B. We tested a few compounds with the serine protease ct-chymotrypsin. 
The inhibitors tested were PhPr-Val -Ala-AAsp-EP-CH 2 CH 2 Ph (23a), PhPr-Val-Ala-AAsp-^z/w-EP-
C O O C H 2 P h (23d) , Cbz-Asp-Glu-Val-AAsp-EP-COOEt (25c, both isomers), and Cbz-Leu-Glu-Thr-AAsp-EP-
COOEt (26c, both isomers). No inhibition of chymotrypsin was observed after 90 minutes of incubation with 
an inhibitor concentration of 223 pM. Granzyme B is thus far the only major mammal ian serine protease which 
cleaves substrates that contain a PI Asp. Since it can also activate caspases and trigger apoptosis, it was 
essential to test our inhibitors with this enzyme. Five inhibitors were tested with granzyme B by Z. Wang and 
Dr. Froelich at Northwestern. The inhibitor Cbz-Leu-Glu-Thr-AAsp-(S,.S)-EP-COOEt (26c, 500 (iM) was 
totally inactive after incubation with enzyme for 1 hour. With PhPr-Val-Ala-AAsp-(S,.S)-EP-COOCH 2 Ph 
(23d), some inhibition was seen over a period of four hours (kobs/[I] < 0.3 M 'V 1). Even less inhibition was 
observed with Cbz-Asp-Glu-Val-AAsp-EP-COOEt (25c, kobs/[I] < 0.1 M 'V 1). The aza-peptide epoxide Cbz-
Ile-Glu-Thr-AAsp-(S,£)-EP-COOEt (27c) did show some inhibition, but was a very weak competitive inhibitor 
(IC50 = 1 0 5 uM) . The activity of the enzyme dropped quickly in the presence of the inhibitor and remained 
almost constant with time. Time-dependent inhibition (if any) was not easily observed (kobS/[I] = 0.65 M 'V 1). 
Coincidently, the best and preferred substrate sequence for granzyme B is Ile-Glu-Pro-Asp, with granzyme B 
almost exclusively preferring isoleucine at P4.(Nicholson and Thornberry 1997) 
Dr. B. Dumi, B. Beyer, and J. Clemente at the U. Florida tested six of our most potent compounds with 
a variety of aspartyl proteases, including porcine pepsin, human cathepsin D, plasmepsin 2 from P. falciparum, 
HIV-1 protease, and the secreted aspartic proteinase 2 (SAP-2) from Candida albicans. After incubation of 
aza-peptide epoxides with enzyme for 20 minutes (30 minutes incubation for HIV-1), no inhibition of more than 
20 percent was observed. 
In summary, aza-peptide epoxide inhibitors are highly specific for clan CD cysteine proteases. 
Effectively, they are non-inhibitors of serine proteases, clan CA cysteine proteases, threonine, and aspartate 
proteases. In contrast, other widely used caspase inhibitors are not specific at all. For example, Cbz-DEVD-
C M K reacts potently with caspase 3 (k 2 /Ki = 1,000,000 M 'V 1) , but also is quite reactive with cathepsin V 
(355,000 M 'V 1 ) , cathepsin L (36,000 M 'V 1), cathepsin B (5200 M 'V 1) , cathepsin S (28,100 M 'V 1 ) , papain 
(1750 M 'V 1 ) , and legumain (660 M 'V 1 ) (Rozman-Pungercar, Kopitar-Jerala et al. 2003). Aza-peptide 
epoxides are more selective than halomethyl ketones as recent experiments have demonstrated that biotinylated 
Cbz-VAD-FMK and A c - Y V A D - C M K can label cathepsin B and cathepsin H (Schotte, Declercq et al. 1999; 
Gray, Haran et al. 2001). 
Stabi l i ty . Aza-peptide epoxides exhibit considerable stability in buffer solutions. The caspase inhibitor 
Cbz-Leu-Glu-Thr-AAsp-(£ ,S)-EP-COOCH 2 Ph (26d, 488 nM) was incubated in buffer containing DTT (50 m M 
Hepes, 0 . 1 % (w/v) CHAPS, 10 m M DTT, at pH 7.4) for 32 minutes, and then substrate (Ac-DEVD-AFC, 100 
\\M) and enzyme (caspase 6, 10 nM) were added and the reaction was monitored. The inhibitor was equally as 
potent as when not incubated with DTT. Aza-peptide epoxides designed for dipeptidyl peptidase I (DPPI) have 
a half-life ( t t / 2 ) of 350 min at pH 7 and 7.5. Aza-peptide epoxides designed for legumain show no 
decomposition after storage for 24 hrs in buffer solutions. One advantage of epoxysuccinyl peptide inhibitors, 
reported in the literature, is their stability under physiological conditions toward simple thiols (Meara and Rich 
1996). At physiological conditions, E-64 does not react with 100 m M cysteine nor does it inactivate lactate 
dehydrogenase, a non-proteolytic thiol-dependent enzyme (Barrett, Kembhavi et al. 1982). 
B ind ing M o d e and M e c h a n i s m . X-ray crystal structures of caspase 1 inhibited by two aza-peptide 
epoxides PhPr-Val -Ala-AAsp-EP-COOCH 2 Ph and PhPr-Val -Ala-AAsp-EP-CH 2 CH 2 Ph have also been 
determined (Ron Rubin, Parke-Davis now Pfizer, unpublished results). Nucleophilic attack by the active site 
Cys 285 of caspase 1 occurs at the C-2 position of the epoxide (5) resulting in a thioester linkage between the 
enzyme and the inhibitor (6). It is clear that the active site cysteine can attack functional groups quite distant 
from the side chain of the PI aza-amino acid residue. We had expected the site of nucleophilic attack to be the 
C-3 position of the epoxide ring. Usually in transition-state inhibitors, such as peptide aldehydes, the active site 
cysteine adds to the aldehyde carbonyl group that is equivalent to the scissile peptide carbonyl group in a 
substrate. 
The selectivity of aza-peptide epoxides for clan CD cysteine proteases is a novel feature of these 
inhibitors. We propose that our aza-peptide epoxides cannot bind in a suitable orientation for effective 
irreversible inhibition in the active sites of papain and other clan CA cysteine proteases, due to the inability of 
the fairly rigid aza-peptide epoxysuccinate moiety to bind properly near the enzyme 's catalytic residues. The 
enzymes in clan CD and clan CA have varying active site topologies, such that the caspase substrate-binding 
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region is quite open and shallow with several binding pockets, while papain has a canyon-like binding site. In 
most caspase inhibitor complexes, the peptide chain of the inhibitor makes antiparallel beta-sheet interactions 
with several residues in the active site of the caspases. The more open active site in the caspases coupled with 
the strict specificity for a P1 Asp residue allows the aza-Asp side chain of the aza-peptide epoxide to bind in the 
SI pocket. This positions the epoxide moiety in close proximity to His 237 and the nucleophilic Cys 285 where 
covalent bond formation can occur. However, in papain, specificity is determined by interaction with the S2 
subsite and a loop structure on the wall of the canyon, which contains the active site histidine, restricts possible 
binding modes of inhibitors. Papain family enzymes form parallel (3-sheet interactions between the enzyme and 
the inhibitor and use an Asn residue to orient the histidine properly in the active site. The caspases only have a 
catalytic dyad, but it is hypothesized that some caspases do use the backbone of residue 177 to create a catalytic 
triad (Stennicke and Salvesen 1998). The distance between the catalytic histidine and cysteine in caspases is 
longer which permits rotation of the histidine, and caspases only use one hydrogen bond to stabilize the 
oxyanion hole versus two hydrogen bonds in papain. These active site differences may contribute to the 
difference in specificity and reactivity observed for aza-peptide epoxides with caspases and clan CA enzymes. 
In the future, we hope to obtain additional crystal structures to confirm our mechanistic hypothesis with other 
caspases. W e were quite surprised at the high specificity of these inhibitors for clan CD cysteine proteases and 
expected at least some reactivity toward other cysteine proteases, which was not observed. 
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Aza-peptide Michael Acceptors. W e next decided to extend the aza-peptide epoxide design (5) to aza-
peptide Michael acceptor inhibitors (7). We synthesized over forty derivatives, a few of which are shown in 
Table 6. Second-order inhibition rates Qc% values in M'V1) are shown for caspase 3, 6, and 8. W e have also 
synthesized inhibitors for legumain and gingipain which will be discussed later. Most of this data is 
unpublished, although we have published a brief communication (Ekici, Gotz et al. 2004). Aza-peptide Michael 
acceptors are potent and selective inhibitors for all the clan CD cysteine proteases examined. The aza-peptide 
Michael acceptors with a P I aza-Asp residue inhibit caspases 3, 6, and 8 with k 2 values in the order of 10 6 M" 
V1 (Table 6). The D E V D and L E T D sequences are optimal sequences for caspase 3 and caspase 8, 
respectively. The D E V D inhibitors are potent inhibitors of caspase 3 (k 2 values range up to 3,000,000), while 
the LETD derivatives are potent inhibitors of caspases 6 and 8 with k 2 values up to 47,600 M'V1 and 237,000 
M'V1, respectively. The dibenzyl amide 9 was one of the most selective compound among the caspases 3, 6, 
and 8, where it inhibits caspase 3 588-fold more potently than caspase 6 and 349-fold more potently than 
caspase 8. The tetrahydroquinoline derivative 10 was a selective caspase 8 inhibitor with a 16-fold selectivity 




Cbz-Asp-Glu-Va l -AAsp-CH=CH-COOCH 2 Ph 
Cbz-Asp-Glu-Va l -AAsp-CH=CH-CONHCH 2 Ph 
Cbz-Asp-Glu-Val -AAsp-CH=CH-CONHCH 2 -4 -F-Ph 
C b z - A s p - G l u - V a l - A A s p - C H = C H - C O N H C H 2 C H 2 P h 
C b z - A s p - G l u - V a l - A A s p - C H = C H - C O N ( C H 3 ) C H 2 P h 
C b z - A s p - G l u - V a l - A A s p - C H = C H - C O N ( C H 3 ) C H 2 C H 2 P h 
C b z - A s p - G l u - V a l - A A s p - C H = C H - C O N ( C H 2 P h ) 2 
Cbz-Asp-Glu-Val-AAsp-CH=CH-CON-tetrahydroquinol ine 
Cbz-Leu-Glu-Thr-AAsp-CH=CH-COOEt 
Cbz-Leu-Glu-Thr -AAsp-CH=CH-COOCH 2 Ph 
Cbz-Leu-Glu-Thr -AAsp-CH=CH-CONHCH 2 -4 -F-Ph 
Cbz-Leu-Glu-Thr-AAsp-CH=CH-CONHPh 
Cbz -Leu -Glu -Thr -AAsp-CH=CH-CON(CH 2 Ph) 2 
Cbz-Leu-Glu-Thr-AAsp-CH=CH-CON-tetrahydroquinol ine 
Cbz -Leu -Glu -Thr -AAsp-CH=CH-CON(CH 3 )CH 2 -1 -Napth 
Cbz - I l e -Glu -Thr -AAsp-CH=CH-CON(CH 2 Ph) 2 
caspase 3 caspase 6 caspase 8 
trans 2,130,000 M" ' s ' 1 35,575 272,960 
cis 1,060,000 11,000 181,000 
trans 1,700,000 8,470 121,000 
trans 1,750,000 3,210 78,235 
trans 2,100,000 4,400 85,100 
trans 1,950,000 3,470 129,000 
trans 2,640,000 9,500 90,300 
trans 1,180,000 4,000 31,900 
trans (9) 3,000,000 5,100 8,600 
trans 2,300,000 5,700 118,000 
trans 5,560 18,700 237,000 
trans 4,600 47,600 98,400 
trans 4,490 3,100 171,000 
trans 4,700 11,400 176,000 
trans 8,630 14,100 129,000 
trans (10) 12,100 13,000 216,000 
trans 11,200 21,700 179,000 
trans (11) 9600 83,900 39,500 
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Our proposed mechanism of inhibition involves attack at carbon 2 of the Michael acceptor 7 to give the 
thioether product 8. It should be noted that the numbering of epoxides and Michael acceptors differ (see 5 and 
7). We favor C-2 attack, since the dienyl derivative Cbz-Val-AAsp-CH=CH-CH=CH-CH3 designed for 
caspases showed no inhibitory potency toward caspases and was also stable when tested for reactivity with 
DTT. In addition, it has previously been shown that simple acrylates are more reactive than simple acrylamides 
to thiol nucleophiles such as glutathione (Freidig, Verhaar et al. 1999). Attack at C-2 is Michael addition to an 
acrylate where R' = an ester, while attack at C-3 is addition to an acrylamide. 
We further investigated the inhibition mechanism by conducting an N M R study of the reaction of the 
inhibitors with the thiol nucleophile benzyl mercaptan. The inhibitor Cbz-Asp-Glu-Val-AAsp-CH=CH-COOEt 
was reacted with benzyl mercaptan, and the reaction was monitored using N M R over 48 hours. The 
formation of a new signal at 4.05 ppm was observed with the simultaneous disappearance of the vinyl proton 
signal at 6.63 ppm. The observed spectrum was consistent with a thioether adduct that is formed by the attack 
of the benzyl mercaptan at the C-2 carbon (7). An attack at the C-3 carbon would result in a chemical shift of 
the C-3 hydrogen at 3.59 ppm as predicted by the additivity rules (Buergin-Schaller, Arnold et al. 1995) used in 
ChemDraw. There was no further change in the spectrum after 48 hours, which indicates that probably a stable 
thioether adduct had formed. The evidence for the mechanism is compelling, but not infallible, and we would 
like to obtain a crystal structure of one of these adducts. 
Stabi l i ty . The aza-peptide Michael acceptors were tested for their reactivity toward thiol nucleophiles 
such as the thiol D T T contained in the assay buffer conditions. The stability of a representative group of 
compounds was studied by monitoring the UV spectrum of buffer solutions of the inhibitors at 250 nm, at 25 
°C. The buffer solutions contained 10 m M D T T and the pH range was 5.8-7.2. The half-lives (ti/2) for the 
esters (7, R = COOR) range from 3-10 min, whereas the monosubstituted amides (7, R = CONHR) were less 
reactive with half-lives of 20-58 min. A caspase specific disubstituted amide analog (R = CONR2) had a half-
life of 116 min, whereas a similar disubstituted amide analog designed for legumain was stable when tested 
over a period of 15 hours. Additional kinetic studies are proposed to elucidate the structural features which 
result in additional stability in aza-peptide Michael acceptor inhibitors. 
L e g u m a i n Aza -pep t ide Inh ib i to r s . W e have applied both the aza-peptide epoxide and Michael 
acceptor design to legumain and synthesized about 30 aza-peptide inhibitors. Table 7 lists kinetic data with 
both S. mansoni and pig kidney legumain. Most of the compounds are epoxides, but the last two inhibitors are 
Michael acceptors. The work with the epoxides has been published (James, Gotz et al. 2003) and one legumain 
inhibitor has been used to develop a cytochemical assay for legumain activity in pig kidney and mouse skin 
(Zeeuwen, van Vlijmen-Willems et al. 2004). With the parasitic blood fluke Schistosoma mansoni legumain, 
Connor Caffrey and Jim McKerrow at UCSF measured IC50 values, and k o b s / [ I ] values for some of the more 
potent inhibitors. Only limited data with the pig kidney enzyme is available since our collaborator, Dr. Alan 
Barrett of the Strangeways Laboratory (Cambridge, England), shut down his wet lab during the course of the 
project to devote full t ime to the protease web site MEROPS. (http://merops.sanger.ac.uk/). 
Tab le 7. S. mansoni (IC5Q & k p b s / [ I ] ) pig kidney ( k p b s / [ I ] ) 
Cbz-Ala-Ala-AAsn-0S*,S)-EP-COOEt 53 nM 17,400 NT's" 43,000 MTV 
Cbz-Ala-Ala-AAsn-OR^-EP-COOEt 788 25,200 
Cbz-Ala-Ala-AAsn-(cw)-EP-COOEt 140 
Cbz-Ala-Ala -AAsn- (£S) -EP-COOCH 2 Ph 47 15,300 26,700 
Cbz-Ala-Ala-AAsn-(5 ,5) -EP-COOCH 2 CH 2 Ph 45 
Cbz-Ala-Ala-AAsn-0S,S)-EP-CON(rcBu) 2 68 
Cbz-Ala-Ala-AAsn-^S, S ) -EP-CON(CH 3 )CH 2 Ph 63 
Cbz-Ala-Ala-AAsii-(^ra/w)-EP-CH 2 CH 2 Ph 70 
Cbz-Ala-Ala-AAsn-(Vra/w)-EP-Ph-4-Cl 90 
Cbz-Ala -Ala -AAsn- t r ans -CH=CH-CON(CH 3 )CH 2 - l -Nap th 35 16,930 
Cbz-Ala-Ala-AAsn- t rans-CH=CH-CON(Bzl) 2 45 5,800 
We tested both classes of legumain inhibitors with other clan CD cysteine proteases, such as caspases, 
gingipain, and clostripain, and clan CA proteases including papain, calpain, and cathepsin B and found little to 
no cross-reactivity. 
Allyl Sulfones-A New Class of Inh ib i to r s F o r Clan C A Cyste ine Pro teases . Peptidyl vinyl sulfones 
are well known irreversible inhibitors for clan CA cysteine proteases and the proteasome (Palmer, Rasnik et al. 
1995; Powers, Asgian et al. 2002). We attempted to combine the vinyl sulfone design with the epoxide 
inhibitors described early and tried to synthesize peptide epoxy sulfones (12). When we took a simple dipeptide 
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vinyl sulfone (13) and treated it with £-BuLi in the presence of an oxidizing agent, we obtained a new 
compound. This new compound was subsequently shown to be a peptidyl allyl sulfone (14), which resulted by 
isomerization of the vinyl sulfone double bond. 
Peptidyl' 













Peptidyl Vinyl Sulfone 
Cbz-AA-AA-VS-Ph 1 3 
H O 
Peptidyl Allyl Sulfone 
Cbz-AA-AA-AS-Ph 
1 4 
The new peptidyl allyl sulfones were tested first with a variety of clan CA cysteine proteases (calpain I, 
papain, cathepsin B, L, cruzain, and rhodesain), since vinyl sulfones are fairly reactive with the group of 
cysteine proteases. Inhibition date is shown in Table 8. This new class of compounds shows moderate rates of 
calpain and papain inactivation and good rhodesain and cruzain inactivation. The oxazoline, also a potential 
product from the base catalyzed isomerization reaction, was also a slow inhibitor of calpain I. Interestingly, the 
allyl sulfones were more reactive than the vinyl sulfone containing the same sequence. At present, we don't 
know if these inhibitors are specific for clan CA cysteine protease or whether they can be extended to clan CD 
enzymes. Currently, we are not developing these inhibitors further because we are focusing on aza-peptides. 
k o b s / p ] ( M " 1 s-1) I C 5 0 ( m M ) 
Tab le 8. Calpain I Papain Cathepsin B Cathepsin L Cruzain Rhodesain 
Cbz-Ala-Phe-AS-Ph 3 9 N.I . 183 >10 >10 
Cbz-Val-Phe-AS-Ph 3 6 N.I. 310 6 5 
Cbz-Leu-Phe-AS-Ph (A) 23 49 N.I. 700 0.06 0.04 
Cbz-Leu-Phe-AS-Ph (B) 564 15 N.I. 1060 0.3 0.18 
Cbz-Leu-Phe-VS-Ph 550 10 N.I. 219 2 0.5 
oxazoline 13 N.I . N.I . N.I . >10 >10 
Allyl sulfone A is derived from the L-isomer of Phe. Allyl sulfone B is derived from the D-isomer of Phe. 
Calpains are a class of calcium activated cysteine proteases. Enhanced calpain activity however has 
been related to cell injury due to ischemic stroke (Bartus, Elliott et al. 1995), physical damage (Seubert, Ivy et 
al. 1988), hypoxia (Lee, Frank et al. 1991), and peripheral neuropathy (Wang, Davis et al. 2004). Cruzain and 
rhodesain are clan CA cysteine proteases, which are essential for the development and survival of the parasite 
Trypansoma brucei, the protozoan parasite species that causes sleeping sickness in humans and cattle. 
Cathepsin B and L are lysosomal cysteine proteases and cathepsin B is associated with invasive breast tumors. 
Apoptos i s Assays (Specific A im 5). Fas induced apoptosis assays in the Jurkat (MTT assay) with 
several aza-peptide epoxides were done in Dr. Guy Salvesen's lab by Dr. Jowita Mikolajczyk and t i e results are 
shown in Table 9. The assays were done with 0 uM (control), 10 uM, and 50 u M of inhibitor. Three 
fluoromethyl ketone (FMK) "caspase specific" inhibitors where also tested in this tissue culture paradigms of 
cell fate decisions to define which are due to caspases and which to other proteases. "The aza-peptide epoxides 
efficiently blocked apoptosis with the same potency as F M K inhibitors, but showed a distinct reduction in 
(artefactual) side effects" (from Jowita Mikolajczyk's abstract to the cell death conference this summer) . The 
caspase 3 inhibitor (15) has also been shown to completely stop apoptosis in the laboratory of Dr. Jonathan 
Glass at Emory University using the Sytox assay (Wang, Davis et al. 2004). 
T a b l e 9. Inhibition of Fas induced apoptosis (% survival). Inh. Cone: 50 u,M 10 u.M 0 u,M 
Control 19 
Cbz-Ile-Glu-Tlir-AAsp-(£ ( S)-EP-C02Et 87 52 
Cbz- l l e -Glu-Thr -AAsp- (^5) -EP-C0 2 Et 88 54 
Cbz-Glu-Val-AAsp-( ( S, ( S)-EP-C0 2 Et 83 60 
Cbz-Asp-Glu-Val -AAsp- (£ ,# ) -EP-C0 2 Et 24 21 
Cbz-Asp-Glu-Val-AAsp-( J S', J S)-EP-C0 2 Et(15) 78 51 
Cbz-Val-Asp-FMK 111 113 
Cbz-Ile-Glu-Thr-Asp-FMK 98 70 
Cbz-Leu-Glu-Thr-Asp-FMK 98 64 
X- ray S t r u c t u r e s of Caspase - Inh ib i to r Complexes . Five crystal structures of caspase-3 : aza-pept ide 
epoxide inhibitor complexes were reported and reveal the structural basis for the mechanism of inhibition and 
the specificities at the ST and the S4 subsites. Unlike the clan CA cysteine proteases, the catalytic histidine in 
caspase-3 plays a critical role during protonation and subsequent ring opening of the epoxide moiety and 
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facilitates nucleophilic attack by the active site cysteine. The nucleophilic attack takes place on the C - 3 carbon 
atom of the epoxide and results in an irreversible alkylation of the active site cysteine residue. A favorable 
network of hydrogen bonds involving the oxyanion hole, catalytic histidine and the atoms in the prime site of 
the inhibitor enhance the binding affinity and specificity of the aza-pept ide epoxide inhibitors towards 
caspase-3 . The studies also reveal that subtle movements of the N- te rmina l loop of the (3-subunit occur, when 
the P4 Asp is replaced by a P4 He, whereas the N- te rmina l loop and the "safety catch" Asp 179 are completely 
disordered when the P4 Asp is replaced by P4 Cbz group. 
Main Protease from the the SARS coronavirus. The main protease ( M p r 0 ) from the coronavirus (CoV) 
causing severe acute respiratory syndrome (SARS) is one of the most attractive molecular targets for the 
development of anti-SARS agents. We reported the crystal structures of SARS-CoV M p r o unbound in the 
crystal form C2, and bound by an aza-peptide epoxide (APE) in the crystal forms C2 and ?2\2\2\, respectively. 
These structures show that the aza-peptide epoxide irreversibly inhibits SARS-CoV M p r o by the formation of a 
covalent bond between the catalytic Cys-145 S atom of the protease and the epoxide C3 atom of the inhibitor. 
The aza-peptide component of APE binds in the substrate-binding regions of SARS-CoV M p r o in a substrate­
like mode. Clues for the optimization of APE:SARS-CoV M p r o binding were described. In addition, the 'N-
fingers' (N-terminal residues 1 to 7) of both protomers of SARS-CoV M p r o are well defined and the substrate-
binding regions of both protomers are in the catalytically competent conformation at the crystallization pH (pH 
6.5). 
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